EP Patent

EP2575821B1 — Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions

Assigned to Satiogen Pharmaceuticals Inc · Expires 2015-08-12 · 11y expired

What this patent protects

Patent listed against Bylvay.

Drugs covered by this patent

Patent Metadata

Patent number
EP2575821B1
Jurisdiction
EP
Classification
—
Expires
2015-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Satiogen Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.